Cromatina / Epigenética
Los inhibidores de cromatina/epigenética son compuestos que modulan la estructura y función de la cromatina o interfieren con modificaciones epigenéticas, como la metilación del ADN y la modificación de histonas. Estos inhibidores son herramientas esenciales para estudiar la regulación de la expresión génica y el papel de la epigenética en enfermedades como el cáncer, los trastornos neurológicos y las anomalías del desarrollo. Al dirigirse a los procesos epigenéticos, estos inhibidores pueden alterar los patrones de expresión génica y ofrecer nuevas vías terapéuticas. En CymitQuimica, ofrecemos una amplia selección de inhibidores de cromatina/epigenética de alta calidad para apoyar su investigación en biología molecular, genética y epigenética.
Subcategorías de "Cromatina / Epigenética"
Se han encontrado 2238 productos de "Cromatina / Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
LSD1/2-IN-4
<p>LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.</p>Fórmula:C9H8BrF2NForma y color:SolidPeso molecular:248.07BRD4-IN-7
CAS:<p>BRD4-IN-7, also known as compound 120, acts as a BRD4 inhibitor.</p>Fórmula:C29H24F2N4O3Forma y color:SolidPeso molecular:514.52MAT2A-IN-16
CAS:<p>MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.</p>Fórmula:C23H17ClN6OForma y color:SolidPeso molecular:428.874JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Fórmula:C16H13IN6Forma y color:SolidPeso molecular:416.22MAT2A-IN-18
CAS:<p>MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.</p>Fórmula:C17H13ClN4OForma y color:SolidPeso molecular:324.764NSD2-PWWP1-IN-1
CAS:<p>NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.</p>Fórmula:C28H30N4Forma y color:SolidPeso molecular:422.565PRMT5-IN-50
CAS:<p>PRMT5-IN-50 is an orally active selective inhibitor of PRMT5, demonstrating good metabolic stability and low clearance in human liver microsomes. It inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50 values for symmetric arginine methylation inhibition at 1.0 and 536 nM, respectively, and antiproliferative IC50 values at 19 and 1620 nM, respectively. Additionally, PRMT5-IN-50 suppresses tumor growth in mice.</p>Fórmula:C26H23F3N6OForma y color:SolidPeso molecular:492.496KH-259
<p>KH-259: potent, selective CNS-penetrant HDAC6 inhibitor with 0.26 μM IC50; shows antidepressant effects in mice.</p>Fórmula:C20H25N3O2Forma y color:SolidPeso molecular:339.43BRD4 Inhibitor-33
CAS:<p>BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].</p>Fórmula:C24H20N4O2Forma y color:SolidPeso molecular:396.44MAT2A-IN-21
CAS:<p>MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.</p>Fórmula:C26H20F2N4O2Forma y color:SolidPeso molecular:458.459MAT2A-IN-20
CAS:<p>MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.</p>Fórmula:C26H24F2N6O4Forma y color:SolidPeso molecular:522.503PRMT5-IN-49
CAS:<p>PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.</p>Fórmula:C19H22N2O2Forma y color:SolidPeso molecular:310.39L-Moses dihydrochloride
<p>L-Moses (L-45) dihydrochloride is the first, potent, selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor (Kd: 126 nM).</p>Fórmula:C21H26Cl2N6Forma y color:SolidPeso molecular:433.38(rac)-Talazoparib
CAS:<p>(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is an orally active inhibitor of PARP1/2, with Ki values of 1.2 nM and 0.87 nM, respectively. It inhibits cellular PARylation at an EC50 of 2.51 nM. This compound leads to the accumulation of DNA damage and suppresses the proliferation of BRCA1/2-mutated MX-1 and Capan-1 cells, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib exhibits antitumor activity in mouse models.</p>Fórmula:C19H14F2N6OForma y color:SolidPeso molecular:380.351HDAC1-IN-3
<p>HDAC1-IN-3 is a potent inhibitor of Pf HDAC1.</p>Fórmula:C22H24ClN7O2Forma y color:SolidPeso molecular:453.92NSD2-PWWP1-IN-2
CAS:<p>NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.</p>Fórmula:C29H30N4Forma y color:SolidPeso molecular:434.5755-AIQ hydrochloride
CAS:<p>5-AIQ hydrochloride is a water-soluble PARP-1 inhibitor and serves as a vital functional group in various medications. It mitigates tissue damage associated with hepatic ischemia-reperfusion, making it valuable for research into conditions related to liver ischemia-reperfusion.</p>Fórmula:C9H9ClN2OForma y color:SolidPeso molecular:196.634QCA570
CAS:<p>QCA570 is an effective BET degrader based on PROTAC (IC50: 10 nM for BRD4 BD1 Protein).</p>Fórmula:C39H33N7O4SPureza:98%Forma y color:SolidPeso molecular:695.79BRD4 D1-IN-1
<p>BRD4 D1-IN-1 selectively inhibits BRD4 D1 (IC50 <0.092 μM, Kd 18 nM) with >500-fold specificity versus D2.</p>Fórmula:C32H37F3N6OForma y color:SolidPeso molecular:578.67MAT2A-IN-17
CAS:<p>MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.</p>Fórmula:C23H18F3N7OForma y color:SolidPeso molecular:465.431SARS-CoV-2 nsp14-IN-1
<p>SARS-CoV-2 nsp14-IN-1 inhibits Nsp14 Mtase with an IC50 of 0.061 μM, affecting multiple substrates.</p>Fórmula:C20H20N6O5SForma y color:SolidPeso molecular:456.48BET/Aurora kinase-IN-1
CAS:<p>BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.</p>Fórmula:C25H30FN7OForma y color:SolidPeso molecular:463.55HDAC-IN-87
CAS:<p>HDAC-IN-87 (Compound XII6) is a non-selective HDAC inhibitor with pIC50 values of 6.9 for HDAC4 and 5.8 for HDAC6. It exhibits fungicidal activity against P. sorghi and P. pachyrhizi. The acute oral LD50 in both male and female rats is greater than 500 mg/kg.</p>Fórmula:C13H7F5N4O2SForma y color:SolidPeso molecular:378.277WDR5-IN-5
CAS:<p>WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.</p>Fórmula:C29H29F3N6OForma y color:SolidPeso molecular:534.58PHD2-IN-4
CAS:<p>PHD2-IN-4 (compound 1) is an inhibitor of PHD2, with an IC50 of 4 nM. It is utilized in research related to chronic kidney disease.</p>Fórmula:C21H19N5O3Forma y color:SolidPeso molecular:389.407GSK3368715 3HCl
CAS:<p>GSK3368715, a potent inhibitor of type I protein arginine methyltransferases (PRMT), could inhibit PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81</p>Fórmula:C20H41Cl3N4O2Pureza:98%Forma y color:SolidPeso molecular:475.92SIRT-IN-6
CAS:<p>SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.</p>Fórmula:C7H4ClN3OSForma y color:SolidPeso molecular:213.644JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Fórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Fórmula:C20H20N4O2SForma y color:SolidPeso molecular:380.463HDAC11-IN-2
CAS:<p>HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.</p>Fórmula:C25H35N3O3Forma y color:SolidPeso molecular:425.564JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62PRMT5-IN-48
CAS:<p>PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).</p>Fórmula:C30H37N5O3Forma y color:SolidPeso molecular:515.646DS79932728
CAS:<p>DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.</p>Fórmula:C19H25N3OForma y color:SolidPeso molecular:311.421FY-56
<p>FY-56: potent, selective LSD1/KDM1A inhibitor (IC50=42nM); differentiates MOLM-13/MV4-11 cells; promising for AML research.</p>Fórmula:C23H19FN2O3Forma y color:SolidPeso molecular:390.41LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Fórmula:C26H31N7O2Forma y color:SolidPeso molecular:473.57HIF-2α-IN-5
CAS:<p>HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].</p>Fórmula:C15H12F4O3S2Forma y color:SolidPeso molecular:380.38JTZ-951 HCl
CAS:<p>JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).</p>Fórmula:C17H17ClN4O4Pureza:98%Forma y color:SolidPeso molecular:376.79lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Fórmula:C16H25N5OSForma y color:SolidPeso molecular:335.468DDO-3055
CAS:<p>DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.</p>Fórmula:C17H13ClN2O5Forma y color:SolidPeso molecular:360.749LSD1-IN-39
CAS:<p>LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.</p>Fórmula:C25H30N2O7Forma y color:SolidPeso molecular:470.515AMPK activator 16
CAS:<p>AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).</p>Fórmula:C23H20ClNO5SForma y color:SolidPeso molecular:457.927NPC26
CAS:<p>NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.</p>Fórmula:C19H23N3O5S2Forma y color:SolidPeso molecular:437.533CREB-IN-1 TFA
<p>CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.</p>Forma y color:SolidNVS-BPTF-1
CAS:<p>NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].</p>Fórmula:C26H28FN7O3SForma y color:SolidPeso molecular:537.61Purinostat
CAS:<p>Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.</p>Fórmula:C23H26N10O3Forma y color:SolidPeso molecular:490.518LSD1-IN-15
<p>LSD1-IN-15 inhibits LSD1, MAO-A/B with IC50s: 0.149, 0.028, 0.327 μM; arrests LNCaP cancer cell growth, IC50 9.9 μM.</p>Fórmula:C22H20N2OForma y color:SolidPeso molecular:328.41GDC-0339
CAS:<p>GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.</p>Fórmula:C20H22F3N7OSForma y color:SolidPeso molecular:465.5PRMT5-MTA-IN-3
CAS:<p>PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It inhibits the proliferation of MTAP-deficient colorectal cancer HCT-116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 holds potential for research in cancers, particularly in MTAP-deficient tumors such as colorectal cancer, non-small cell lung cancer, and pancreatic cancer.</p>Fórmula:C19H17F3N6O3Forma y color:SolidPeso molecular:434.372Pociredir
CAS:<p>Pociredir (FTX-6058), a potent EED inhibitor (KD=0.163 nM), may help in SCD research.</p>Fórmula:C22H18FN5O2Forma y color:SolidPeso molecular:403.41PARP-1/HDAC-IN-1
CAS:<p>PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.</p>Fórmula:C22H18N4O4Pureza:95.94%Forma y color:SolidPeso molecular:402.4
